

AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims in this Application.

LISTING OF CLAIMS

1. (currently amended) A needle-shaped solid pharmaceutical composition for parenteral injection, ~~said composition having the shape of a needle capable of penetrating cutis or mucosa,~~ comprising a binder, and at least one therapeutic agent, ~~said and,~~ optionally, at least one non-crystallization non-crystallisation agent,

wherein the binder constituting constitutes at least 0.5% by weight of the composition, comprises and said binder comprising at least one binding agent being a carbohydrate binding agent, and forms an amorphous matrix,

~~and said the~~ therapeutic agent ~~comprises~~ constitutes at least 25% ~~40%~~ 25% by weight of the composition by weight and is distributed homogeneously throughout the composition, and

the said composition comprising optionally at least one non-crystallisation agent, whereby said binder forms an amorphous matrix, and whereby such composition is injectable without dissolution or other reconstitution and wherein, the therapeutic agent is distributed homogeneously throughout the composition capable of penetrating cutis or mucosa.

2. (currently amended) The composition ~~according to~~ of claim 1, wherein the binder constitutes ~~from 5-60% by weight~~ of the composition by weight

3. (currently amended) The composition ~~according to~~ of claim 1, wherein the binder essentially remains an amorphous matrix for at least 6 months at ambient temperature.

Attorney Docket No. 5866.200-US
S/N 09/550,857 Filed April 17, 2000
Express Mail Label No. EV 246879232 US

4. (currently amended) The composition of ~~according to~~ claim 1, wherein the binder can endure a pressure force of at least 10 Newton.

5. (currently amended) The composition of ~~according to~~ claim 1, wherein the composition can endure a pressure force of at least 5 Newton.

6. (cancelled)

7. (currently amended) The composition of ~~according to~~ claim 1, wherein the composition is essentially free from entrapped air.

8. (cancelled)

9. (currently amended) The composition of ~~according to~~ claim 1, having wherein the composition has the shape of a an essentially cylindrical rod essentially cylindrical and comprising one pointed at one end.

10. (currently amended) The composition of ~~according to~~ claim 9, wherein the top angle of the rod is between 10 °C and 110 °C.

11. (currently amended) The composition according to claim 8 ~~or~~ 9, wherein the maximum cross section of the composition pellet is less than 1 mm.

12. (currently amended) The composition of ~~according to~~ claim 9, ~~whereby~~ wherein the length of the rod is less than 10 mm.

13. (currently amended) The composition of ~~according to~~ claim 1, wherein the

Attorney Docket No. 5866.200-US
S/N 09/550,857 Filed April 17, 2000
Express Mail Label No. EV 246879232 US

volume of the composition is less than 5 μ l.

14. (currently amended) The composition ~~according to~~ of claim 1, wherein the composition can penetrate the epidermis of a human being with a force less than 5 Newton.

15. (cancelled)

16. (currently amended) The composition ~~of according to~~ of claim 1, wherein the binder ~~constitutes comprises~~ at most 50 % of the composition by weight ~~of the composition~~.

17. (currently amended) The composition ~~of according to~~ of claim 1, wherein the at least one carbohydrate binding agent comprises from 50 % and 97 % ~~by weight~~ of the binder by weight.

18. (currently amended) The composition ~~of according to~~ of claim 1, wherein the at least one ~~non-crystallization non-crystallisation~~ agent ~~constitutes comprises~~ at least 1 % ~~by weight~~ of the binder by weight.

19. (currently amended) The composition ~~according to~~ of claim 1, wherein the water content of the binder is less than 20 % by weight.

20. (currently amended) The composition ~~of according to~~ of claim 1, wherein the at least one binding agent ~~being a carbohydrate~~ is a mono-, di-, or oligosaccharide or a corresponding sugar alcohol.

21. (currently amended) The composition ~~of according to~~ of claim 20, wherein the at least one binding agent is ~~selected from~~ maltose, sucrose, lactose, cellobiose, trehalose,

Attorney Docket No. 5866.200-US
S/N 09/550,857 Filed April 17, 2000
Express Mail Label No. EV 246879232 US

maltulose, iso-maltulose, maltitol, sorbitol, mannitol, glucose, fructose, raffinose, melezitose, dextran, mannose, sorbose, melibiose, sophrose, turanose, lactulose, or stachyose.

22. (currently amended) The composition of ~~according to~~ claim 1, wherein the at least one ~~non-crystallisation~~ non-crystallization agent is a carbohydrate, ~~said carbohydrate being that is~~ different from the binding agent.

23. (currently amended) The composition ~~according to~~ of claim 22, wherein the at least one ~~non-crystallisation~~ non-crystallization agent is a mono-, di-, or oligosaccharide, a corresponding sugar alcohol, or a derivative thereof.

24. (currently amended) The composition of ~~according to~~ claim 22, wherein the at least one ~~non-crystallisation~~ non-crystallization agent is ~~selected from~~ maltose, sucrose, lactose, cellobiose, trehalose, maltulose, iso-maltulose, maltitol, sorbitol, mannitol, glucose, fructose, raffinose, melezitose, dextran, mannose, sorbose, melibiose, sophrose, turanose, lactulose, or stachyose.

25. (currently amended) The composition ~~according to~~ of claim 1, wherein the binding agent is ~~selected from~~ maltitol, sucrose, sorbitol, and or mannitol and the ~~non-crystallisation~~ non-crystallization agent is ~~selected from~~ sorbitol, maltitol, and or mannitol.

26. (currently amended) The composition of ~~according to~~ claim 1, wherein the binding agent is maltitol and the non-crystallization ~~non-crystallisation~~ agent is sorbitol and/or sugar alcohol of maltotriose and higher oligosaccharides.

27. (currently amended) The composition of ~~according to~~ claim 1, wherein the T_g (~~glass transition temperature~~) of the binder is at least 30 °C.

28. (currently amended) The composition of according to claim 1, wherein the Tg of the binder is from 40 °C to 120 °C.

29. (currently amended) The composition of according to claim 1, wherein the viscosity of the composition is less than 50,000 Pa*s in a sub-range of a temperature interval between 60 °C and 140 °C.

30. (currently amended) The composition of according to claim 1, wherein the composition is injection moldable ~~mouldable~~ in a sub-range of the temperature interval between 60°C and 140°C.

31. (currently amended) The composition of according to claim 1, wherein at least 50% of the therapeutic agent is released from the composition within 60 minutes ~~min~~ after injection.

32. (currently amended) The composition according to claim 1, wherein the therapeutic agent is selected from the group consisting of analgesics, antianxiety drugs, antiarthritic drugs, antibiotic agents, anticholinergics, antidepressants, antidiabetics, antiemetics, antihistaminics, antihypertensive agents, antiinflammatory drugs, antimigraine agents, antiparkinsonism agents, antipasmodics, antipsychotics, antithrombotic agents, antiviral agents, appetite suppressants, blood factors, cardiovascular drugs, cerebral vasodilators, chemotherapeutic drugs, cholinergic agonists, contraceptives, coronary agents, diuretics, hormonal agents, immunosuppressive agents, growth factors, narcotic antagonists, opioids, peripheral asodilators, tranquilizers, vaccines, immunogenic agents, and ~~immunising~~ immunization agents.

33. (currently amended) The composition of according to claim 1, wherein the therapeutic agent is selected from the group consisting of hormones, lipids, nucleic acids, nucleotides, oligonucleotides, oligosaccharides, organics, peptide mimetics, antibodies, peptides, polysaccharides, and proteins.

34. (currently amended) The composition of according to claim 1, wherein the therapeutic agent is selected from the group consisting of proteins, peptides, and polypeptides, said wherein the protein, peptide, or polypeptide being is amorphous or crystalline.

35. (currently amended) The composition of according to claim 1, wherein the therapeutic agent is selected from the group consisting of hormones, antidiabetic drugs, growth factors, and blood factors.

36-38 (cancelled)

39. (currently amended) The composition of according to claim 1, wherein the composition is provided with a coating.

40. (currently amended) A method for preparing a solid pharmaceutical composition for parenteral injection comprising[,] mixing at least one therapeutic agent that constitutes at least 40% of the composition by weight homogeneously with a binder, ~~obtaining an amorphous melt matrix, wherein the binder~~ that comprises at least one carbohydrate binding agent being a carbohydrate and constitutes 0.5-60% of the composition by weight, and, optionally, at least one non-crystallization non-crystallisation agent, so as to obtain an amorphous melt matrix ~~said binder constituting at least 0.5% by weight of the composition and at most 75% by weight of the composition, and said therapeutic agent comprising at least 25% by weight of the composition,~~ shaping the melt matrix to a predetermined geometry, cooling to below the T_g (glass transition

Attorney Docket No. 5866.200-US
S/N 09/550,857 Filed April 17, 2000
Express Mail Label No. EV 246879232 US

~~temperature~~) of the binder ~~obtaining the composition, and~~ removing the composition from the ~~mould~~ mold cavity.

41. (currently amended) The method ~~according to~~ of claim 40, wherein the melt is injected into a ~~mould~~ mold cavity having a predetermined geometry.

42. (currently amended) The method ~~according to~~ of claim 40, wherein the method further comprising a heating step comprises applying heat to obtain the an amorphous matrix prior to mixing the therapeutic agent and binder composition.

43. (currently amended) The method ~~of according to~~ of claim 40, wherein, prior to melting, the binder is dissolved in a solvent, ~~dried, and dried to obtaining~~ a solid amorphous matrix, and, optionally, disintegrated ~~disintegrating the binder~~ into a powder.

44. (currently amended) The method ~~of according to~~ of claim 40, wherein the binder and the at least one therapeutic agent are mixed homogeneously as powders and the mixture is melted to form the melt ~~afterwards~~.

45. (currently amended) The method ~~according to~~ of claim 43, wherein the solvent is water.

46. (currently amended) The method ~~of according to~~ of claim 40, wherein the water content of the composition is less than 20 % by weight.

47. (currently amended) The method ~~of according to~~ of claim 40, wherein the Tg of the binder is at least 30°C.

Attorney Docket No. 5866.200-US
S/N 09/550,857 Filed April 17, 2000
Express Mail Label No. EV 246879232 US

48. (currently amended) The method of according to claim 40, wherein the viscosity of the composition is less than 50,000 Pa*s in a sub-range of the temperature interval between 60°C and 140°C.

49. (currently amended) The method of according to claim 40, wherein the steps of the method ~~are carried out~~ is performed under essentially aseptic conditions aseptically.

50. (currently amended) The method of according to claim 40, wherein the composition is molded as the second part in a two component molding machine.

51. (currently amended) The method of according to claim 50, wherein a cartridge constituting the mold cavity is molded as the first part in a two component molding machine.

52. (currently amended) A ~~The~~ method of injecting a solid pharmaceutical composition ~~as defined by claim 1~~ through epidermis or mucosa comprising positioning ~~arranging~~ a device comprising the solid composition of claim 1 adjacent to the epidermis or mucosa and ejecting the solid composition so as to inject the composition through the epidermis or mucosa.

53. (currently amended) The method of according to claim 52, wherein the animal is selected from the group consisting of fish, birds, ~~molluses~~ mollusks, reptiles, ~~or~~ and mammals.

54. (currently amended) The method of according to claim 52, wherein the composition is injected at least once a day.

55. (currently amended) A method of immunizing a mammal against a disease comprising performing the method of claim 52 using a composition wherein the therapeutic

Attorney Docket No. 5866.200-US
S/N 09/550,857 Filed April 17, 2000
Express Mail Label No. EV 246879232 US

agent promotes an immunity-conferring response in the mammal ~~The method according to claim 52 for immunisation.~~

56-58. (cancelled)

59. (currently amended) The method ~~according to~~ of claim 52, wherein the animal is ~~man~~ a human.

60. (new) The composition of claim 1, wherein the composition comprises a pellet-shaped section having a substantially cylindrical, triangular, square, or polygonal cross section.

61. (new) The composition of claim 1, wherein the binder does not reduce the stability of the therapeutic agent.

62. (new) The composition of claim 1, wherein both the at least one binding agent and the at least one non-crystallization agent are non-reducing sugars.

63. (new) The composition of claim 1, wherein the composition comprises an additive selected from the group consisting of preservatives, adjuvants, stabilizers, lubricants, and disintegrators.

64. (new) A solid needle-shaped pharmaceutical composition comprising a binder that forms an amorphous matrix, at least one therapeutic agent, and, optionally, at least one non-crystallization agent, wherein the binder consists essentially of maltitol and the composition is capable of penetrating cutis or mucosa by injection without dissolution or other reconstitution.

65. (new) The composition of claim 64, wherein the composition comprises one or

Attorney Docket No. 5866.200-US
S/N 09/550,857 Filed April 17, 2000
Express Mail Label No. EV 246879232 US

more non-crystallization agents selected from the group consisting of sorbitol, hydrogenated oligosaccharides, and combinations thereof.

66. (new) A solid needle-shaped pharmaceutical composition comprising a binder that forms an amorphous matrix and at least one therapeutic agent, and, optionally, at least one non-crystallization agent, wherein the composition is primarily composed of maltitol and the composition is capable of penetrating cutis or mucosa by injection without dissolution or other reconstitution.

67. (new) The composition of claim 66, wherein the composition comprises one or more non-crystallization agents selected from the group consisting of sorbitol, hydrogenated oligosaccharides, and combinations thereof.

68. (new) The composition of claim 1, wherein the therapeutic agent is a protein, peptide, or polypeptide.